PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Allergy and Infectious Diseases, Department of Medicine, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington School of Medicine, Seattle, WA, United States of America.\', \'Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory (PNNL), Richland, WA, United States of America.\', \'Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA, United States of America.\', \'Department of Microbiology, University of Washington School of Medicine, Seattle, WA, United States of America.\', \'School of Molecular Bioscience, Washington State University, Pullman, WA, United States of America.\', \'Bioenergy and Biome Sciences, Los Alamos National Laboratory (LANL), Los Alamos, NM, United States of America.\', \'Calibr, a division of The Scripps Research Institute, La Jolla, CA, United States of America.\', \'Institute for Antiviral Research, Utah State University, Logan, UT, United States of America.\', \'Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.\', \'Department of Global Health, University of Washington, Seattle, WA, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1371/journal.pone.0250019
?:doi
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 33886614
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
?:title
  • High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all